Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin in metastatic breast cancer
NCT00386087Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzastaurin in breast cancer, sponsored by Eli Lilly and Company. Primary endpoint: Tumor Size Reduction. Started Nov 2006; status: completed.
02
Drugs
enzastaurin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00386087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386087.